SEARCH RESULTS FOR:

United States
Pharma & Life Sciences

Bassil Dahiyat

PRESIDENT AND CEO, XENCOR
United States Biopharmaceuticals 2019 Pre-Release Edition
Powered by its XmAb antibody engineering platform, Xencor is developing a broad pipeline of drug candidates that are optimized to treat autoimmune disorders, cancer, asthma and allergic diseases.
Mining
Canada

B.C. Mining Enters an Era of Reconciliation

British Columbia Mining 2019 Pre-Release Edition
True cohesion between government, Indigenous groups and the sector is the priority.
Mining
Canada

Metals and Materials of the Future

Québec Mining 2019 Pre-Release Edition
Lithium and vanadium projects are attracting substantial investment.
Mining
Peru

Paul Murphy

MANAGER SOUTH AMERICA, MINING PLUS
Mining Plus, which provides technical services around the world, is growing its South American presence.
Mining
Canada

Dominique Doucet

FOUNDER & CEO, SIRIOS RESOURCES
Québec Mining 2019 Pre-Release Edition
Pioneers in the discovery of world-class gold deposits in the James Bay region, Sirios has discovered numerous showings in Nord-du-Québec and Eastern Canada.
Mining
Cote d’Ivoire
Senegal
Burkina Faso
MACIG

Maname Fall

MANAGER & ASSOCIATE, SOJUFISC
THE OFFICIAL MINING IN AFRICA COUNTRY INVESTMENT GUIDE (MACIG) 2019
SOJUFISC is a Senegalese law firm focused on supporting business in natural resources.
Mining
Canada

Bill Xue

PRESIDENT & CEO, WESTERN RESOURCES
TSX-listed Western Resources’ wholly owned subsidiary Western Potash Corp is fo-cused on developing the Milestone potash project in Saskatchewan.
United States
Pharma & Life Sciences

United States Biopharmaceuticals 2019 Pre-Release Edition

Mining
Canada

Glenn J. Mullan

P.Geo ICD.D. CHAIRMAN OF THE BOARD, President & CEO, GOLDEN VALLEY MINES
Québec Mining 2019 Pre-Release Edition
Golden Valley Mines is based in Quebec and focused on early exploration and grassroots project generation in Canada and beyond.
United States
Pharma & Life Sciences

Standing Out in the Biotech Crowd: The VC Investment Climate

With biotechs now accounting for 70% of clinical trials in the United States, the VC private investment climate is heating up.

MACIG

SPANISH

SUBSCRIBE TO OUR NEWSLETTER

RECENT PUBLICATIONS

United States Life Sciences 2025 - Digital Interactive

Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
MORE PREVIOUSLY PUBLISHED

PARTNER EVENTS

SEE ALL